Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sientra Inc (SIEN), TESARO Inc (TSRO) and Clovis Oncology Inc (CLVS): Orbimed’s Top New Picks

Page 1 of 2

Samuel Islay‘s Orbimed Advisors has revealed its equity portfolio as of end of 2014, in a recent filing with the Securities and Exchange Commission. The top new picks of the fund included: Sientra Inc (NASDAQ:SIEN), TESARO Inc (NASDAQ:TSRO), Clovis Oncology Inc (NASDAQ:CLVS). All these health care companies are small-caps, and from an investor’s point of view the importance of these cannot be stressed enough. According to our research, blindly replicating the most popular hedge fund picks is of much less value to an investor, than following the small cap picks of these investment firms. Analyzing data between 1999 and 2009, we have concluded that hedge funds only beat the beat the market by 2.0 percentage points on an annual basis, while returns from their small cap picks during the same period were in double digits.


Orbimed Advisors’ main focus is the healthcare industry as nearly 96% of the fund’s holdings are in this sector. Samuel Islay formed a team of 80 professionals who are experts in the life sciences industry, medicine, finance and law. Market value of the Orbimed’s portfolio stood at $10.46 billion at the end of the fourth quarter, compared with $9.57 billion a quarter earlier. Besides the three new positions that we will discuss here, the fund initiated holdings in 50 other companies and increased their stake in 53 previously held stocks, according to the recent 13F filing. The portfolio itself is well diversified with top 10 positions comprising just 36.27% of the total value.

Islay disclosed 3.19 million shares of Sientra Inc (NASDAQ:SIEN) valued at $53.48 million to put it at the top of the list of new holdings. Since its IPO in October last year, Sientra is up by about 18.1%. The $290.86 million producer of silicon gel breast implants has a portfolio of 120 different varieties. According to the company, the market for their products stood at $600 million in 2013. Major competitors include Mentor (a division of Johnson & Johnson (NYSE:JNJ)) and Allergan, Inc. (NYSE:AGN). Among the 737 hedge funds that we track at Insider Monkey, Jacob Gottlieb‘s Vissum Asset Management purchased 1.48 million shares valued at $273.86 million during the fourth quarter. Sientra Inc (NASDAQ:SIEN)’s third quarter financial results included revenues of $10.67 million, which were 33.7% higher than same quarter last year, and a net loss per share of $6.94.

Next in line is TESARO Inc (NASDAQ:TSRO) with Islay adding 1.33 million shares valued at $49.46 million to Orbimed’s portfolio. The stock is up 83% over the last 52 weeks. Although the therapeutic drugs sector has generally performed well during this period, Tesaro’s returns of some 80% in the last 52 weeks are over 30 percentage points above the industry’s annual return. In recently reported fourth-quarter financial results TESARO Inc (NASDAQ:TSRO)’s net loss per share of $1.33 missed the $0.30 estimate. The oncology-focused biopharmaceutical company also raised nearly $180 million in a recent equity offering.

Our data shows that despite a loss in popularity among hedge funds over the fourth quarter, as the number of firms decreased to 16 from 20 a quarter earlier, the aggregate amount of capital that hedge funds had invested in TESARO Inc (NASDAQ:TSRO) increased to $961.1 million from $428.45 million. Among these funds, Hal Mintz’s Sabby Capital increased its stake by 5.97 million shares to 6 million shares valued at $747.75 million during the fourth quarter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!